Eli Lilly's recent growth is largely driven by the momentum of its medication Mounjaro, alongside an increasing interest in GLP-1 drugs.
Barclays has expressed a bullish perspective on the company's prospects, suggesting confidence in its ongoing performance.
The combination of these factors positions Eli Lilly favorably in the competitive pharmaceutical market.